Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Andrew Stephen Yates"'
Publikováno v:
Pharmaceuticals, Vol 13, Iss 9, p 219 (2020)
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic
Externí odkaz:
https://doaj.org/article/c232b18773a94e3fbad4c4040432062b
Autor:
Andrew Stephen Yates, Blair William Gibbs, Saoirse E. O'Sullivan, Nicholas James Clarkson, Jonathan Paul Liebling
Publikováno v:
Cannabis Cannabinoid Res
INTRODUCTION: Over-the-counter cannabidiol (CBD) products have seen unprecedented recent growth in the United Kingdom. However, analysis of these predominantly unregulated products from other countries tells us that they are often mislabeled or conta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be86fca2ddd89bea14039b96c4c1485d
https://europepmc.org/articles/PMC9070743/
https://europepmc.org/articles/PMC9070743/
Publikováno v:
Molecules, Vol 26, Iss 6178, p 6178 (2021)
The cannabinoid 1 (CB1) receptor regulates appetite and body weight; however, unwanted central side effects of both agonists (in wasting disorders) or antagonists (in obesity and diabetes) have limited their therapeutic utility. At the peripheral lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b776780aec90f9ad4f4355cd64943c7d
https://www.mdpi.com/1420-3049/26/20/6178
https://www.mdpi.com/1420-3049/26/20/6178
Autor:
Timothy J. England, Z.D. Bellman, Sophie A. Millar, Andrew Stephen Yates, Nicole L. Stone, Saoirse E. O'Sullivan
Publikováno v:
British Journal of Clinical Pharmacology
Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in a wide‐variety of contexts; however, its effective dose in different disease states remains unclear. This review aimed to investigate what doses have bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3bc7befe57d56f2da6d33272b809ca2
https://doi.org/10.1111/bcp.14038
https://doi.org/10.1111/bcp.14038
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 13, Iss 219, p 219 (2020)
Pharmaceuticals, Vol 13, Iss 219, p 219 (2020)
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f372be15349da6856233ff91f90e32ae
https://pubmed.ncbi.nlm.nih.gov/32872355
https://pubmed.ncbi.nlm.nih.gov/32872355
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 9 (2018)
Frontiers in Pharmacology, Vol 9 (2018)
Background: Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to colla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59432f23586b8d1003125a864f01f30d
http://europepmc.org/articles/PMC6275223
http://europepmc.org/articles/PMC6275223